title: Immune selection of tumor cells in TCR β-chain transgenic mice.
abstract: The concept of immunological surveillance implies that immunogenic variants of tumor cells arising in the organism can be recognized by the immune system. Tumor progression is provided by somatic evolution of tumor cells under the pressure of the immune system. The loss of MHC Class I molecules on the surface of tumor cells is one of the most known outcomes of immune selection. This study developed a model of immune selection based on the immune response of TCR 1d1 single β-chain transgenic B10.D2(R101) (K(d)I(d)D(b)) mice to allogeneic EL4 (H-2(b)) thymoma cells. In wild-type B10.D2(R101) mice, immunization with EL4 cells induced a vigorous CTL response targeted to the H-2K(b) molecule and results in full rejection of the tumor cells. In contrast, transgenic mice developed a compromised proliferative response in mixed-lymphocyte response assays and were unable to reject transplanted allogeneic EL4 cells. During the immune response to EL4 cells, CD8(+) T-lymphocytes with endogenous β-chains accumulated predominantly in the spleen of transgenic mice and only a small part of the T-lymphocytes expressing transgenic β-chains became CD8(+)CD44(+)CD62L(-) effectors. Then, instead of a full elimination of tumor cells as in wild-type mice, a reproducible prolonged equilibrium phase and subsequent escape was observed in transgenic mice that resulted in death of 90% of the mice in 40-60 days after grafting. Prolonged exposure of tumor cells to the pressure of the immune system in transgenic mice in vivo resulted in a stable loss of H-2K(b) molecules on the EL4 cell surface. Genetic manipulation of the T-lymphocyte repertoire was sufficient to reproduce the classic pattern of interactions between tumor cells and the immune system, usually observed in reliable syngeneic models of anti-tumor immunity. This newly-developed model could be used in further studies of immunoregulatory circuits common for transplantational and anti-tumor immune responses.
authors.affiliation: Laboratory of Regulatory Mechanisms in Immunity, Carcinogenesis Institute, N. N. Blokhin Cancer Research Center , RAMS, Moscow , Russia.
authors.forename: Yulia Yu
authors.initials: YY
authors.lastname: Silaeva
authors.forename: Tatyana S
authors.initials: TS
authors.lastname: Grinenko
authors.forename: Murad S
authors.initials: MS
authors.lastname: Vagida
authors.forename: Anastasia A
authors.initials: AA
authors.lastname: Kalinina
authors.forename: Ludmila M
authors.initials: LM
authors.lastname: Khromykh
authors.forename: Dmitry B
authors.initials: DB
authors.lastname: Kazansky
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D060966:Clonal Selection, Antigen-Mediated / Q000235:genetics; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D019674:Genes, T-Cell Receptor beta / Q000235:genetics; D006183:H-2 Antigens / Q000276:immunology; D006801:Humans; D007157:Immunologic Surveillance; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D023421:Models, Animal; D009368:Neoplasm Transplantation; D013945:Thymoma / Q000276:immunology*; D014184:Transplantation, Homologous; D019139:Tumor Escape
chemical_list: D006183:H-2 Antigens; C032876:H-2Kb protein, mouse
keywords: Allogeneic tumor; T-cell receptor; immune selection; immunological surveillance; major histocompatibility complex; transgenic mice